1
|
Wang Y, Xuan H, Zhao T, Li X, Li S, Hu W. A study of linear measurement and clinical correlation of brain atrophy in Wilson's disease. Front Hum Neurosci 2023; 17:1142082. [PMID: 37056963 PMCID: PMC10086176 DOI: 10.3389/fnhum.2023.1142082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 02/14/2023] [Indexed: 03/30/2023] Open
Abstract
Background The aim of this study was to explore the clinical relevance of linear measures of Wilson's disease (WD). Methods Relative values of brain atrophy in 30 patients with WD and 30 healthy volunteers were measured and compared using a manual measurement method. Linear measurement indicators of brain atrophy in patients with and without mental disorders were also compared. In addition, correlations of patients' age, disease duration, and Unified Wilson's Disease Rating Scale (UWDRS) scores with brain atrophy indicators were determined. Results The results showed that the e-value, Huckman number, Evans index, and lateral ventricular body index were higher in the WD group compared with the control group. The age of patients with WD was negatively correlated with the k-value and significantly positively correlated with the brainstem index. WD duration was prominently positively correlated with the d-value and negatively correlated with the j-value. In addition, neurological function scores were significantly positively correlated with the c-value, e-value, caudate nucleus index, Huckman number, Evans index, and lateral ventricular body index. By contrast, patients with psychiatric symptoms had a higher a-value and fourth ventricular index than those without psychiatric symptoms. Conclusion Therefore, it can be concluded that patients with WD and those with psychiatric symptoms have more severe brain atrophy compared to normal subjects. The patient's age, disease duration, and neurological function scores were positively correlated with the severity of brain atrophy.
Collapse
Affiliation(s)
- Yun Wang
- Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Hongxia Xuan
- Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
- Department of Neurology, Hongda Hospital, Jiamusi University, Jiamusi, China
| | - Tun Zhao
- Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Xiaodong Li
- Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Shujuan Li
- Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Wenli Hu
- Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
2
|
Murillo O, Collantes M, Gazquez C, Moreno D, Hernandez-Alcoceba R, Barberia M, Ecay M, Tamarit B, Douar A, Ferrer V, Combal JP, Peñuelas I, Bénichou B, Gonzalez-Aseguinolaza G. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease. Mol Ther Methods Clin Dev 2022; 26:98-106. [PMID: 35795774 PMCID: PMC9234538 DOI: 10.1016/j.omtm.2022.06.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 06/03/2022] [Indexed: 11/28/2022]
Abstract
Wilson’s disease (WD) is an inherited disorder of copper metabolism associated with mutations in ATP7B gene. We have shown that the administration of an adeno-associated vector (AAV) encoding a mini version of human ATP7B (VTX-801) provides long-term correction of copper metabolism in a murine WD model. In preparation of a future clinical trial, we have evaluated by positron emission tomography (PET) the value of 64Cu biodistribution, excretion pattern, and blood kinetics as pharmacodynamic biomarkers of VTX-801 effects. Six-week-old WD mice were injected intravenously with increasing doses of VTX-801 and 3 weeks or 3 months later with [64Cu]CuCl2. Untreated WD and wild-type (WT) mice were included as controls. Control WD mice showed increased hepatic 64Cu retention, reduced fecal excretion of the radiotracer, and altered 64Cu blood kinetics (BK) compared with WT mice. VTX-801 treatment in WD mice resulted in a significant reduction of hepatic 64Cu accumulation, the restoration of fecal 64Cu excretion, and the correction of 64Cu BK. This study showed that VTX-801 restores physiological copper metabolism in WD mice, confirming the mechanism of action of VTX-801, and demonstrated the translational potential of [64Cu]CuCl2-PET to explore VTX-801 pharmacodynamics in a minimally invasive and sensitive manner in WD patients.
Collapse
Affiliation(s)
- Oihana Murillo
- Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain
| | - Maria Collantes
- Department of Nuclear Medicine, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain.,Translational Molecular Imaging Unit, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain
| | - Cristina Gazquez
- Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain
| | - Daniel Moreno
- Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain
| | - Ruben Hernandez-Alcoceba
- Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain
| | - Miren Barberia
- Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain
| | - Margarita Ecay
- Translational Molecular Imaging Unit, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain
| | | | | | | | | | - Ivan Peñuelas
- Department of Nuclear Medicine, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain.,Translational Molecular Imaging Unit, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain
| | | | - Gloria Gonzalez-Aseguinolaza
- Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain.,Vivet Therapeutics S.L., Pamplona, Spain
| |
Collapse
|